GlobeNewsWire
24 Feb 2026, 17:02 UTC · 38w ago
AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALS
Impact · against what's priced in
AB Science has identified a plasma biomarker for masitinib that potentially improves patient selection and regulatory pathways across ALS, MS, and Alzheimer's. This increases the probability of clinical success and the potential for accelerated approval via surrogate endpoints.
- AB+0.60
No priced-in read yet





